ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
This study aims to investigate whether patients switching their backbone from Kivexa to
Truvada, who already have raised total cholesterol prior to switching, have an improvement in
their total cholesterol after 12 weeks of treatment. If an improvement is demonstrated the
study aims to show whether this has a beneficial effect on the patient's overall
cardiovascular risk and long term prognosis.
Phase:
Phase 4
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Abacavir Efavirenz Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Lamivudine